Platelet–lymphocyte and neutrophil–lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer

Abstract

It is shown a better prognostic relationship between PLR and NLR low values and OS that is statistically significant in mCPRC patients treated with abiraterone. Furthermore, it was not shown a relation between PLR and NLR values and PSA response.

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature

“…A high PLR has been shown to predict poor prognoses in various cancers such as hepatocellular carcinoma, breast cancer, urological cancers, and pancreatic cancer . This is consistent with the results from both included studies which show that patients with a higher PLR had significantly lower overall survival rates, demonstrating the prognostic value of this laboratory marker in mCRPC patients treated with abiraterone . Based on these findings, our patient's PLR, which was 320.8, should be associated with a poorer overall survival.…”

“…With the implementation of the other inclusion and exclusion criteria, and reviewing retrieved full text articles, two articles were included in the final analysis. These were studies done by Martinez et al and Lolli et al…”

“…Martinez et al explored the relationship between PLR and the survival rates in 101 mCRPC patients treated with abiraterone, with 45 receiving previous docetaxel therapy. This study reported that high values of PLR (>210) reflected a significantly worse prognosis in terms of overall survival in mCRPC patients (15.9 vs 27.4 months, P = 0.005), which was analyzed by logrank test . Lolli et al conducted a study with 230 mCRPC patients, evaluating the prognostic role of systemic immune‐inflammation index (SII) in mCRPC patients who received abiraterone with previous docetaxel treatment.…”

“…This study reported that high values of PLR (>210) reflected a significantly worse prognosis in terms of overall survival in mCRPC patients (15.9 vs 27.4 months, P = 0.005), which was analyzed by logrank test. 15 Lolli et al conducted a study with 230 mCRPC patients, evaluating the prognostic role of systemic immune-inflammation index (SII) in mCRPC patients who received abiraterone with previous docetaxel treatment. Lolli et al 16 also found that a high PLR (>150) is significantly associated with shorter overall survival (14.4 vs 19.0 months, P = 0.002), with a hazard ratio (HR) of 1.68 (1.20-2.35), analyzed by cox proportional hazard regression models ( Table 2).…”

“…Both included studies are retrospective in nature, which is more sensitive to bias than prospective cohort studies. Additionally, Martinez et al included patients with and without a history of previous docetaxel therapy, prior to abiraterone, without performing subgroup analyzes between these two groups. Previously, abiraterone was only indicated in mCRPC patients with previous docetaxel therapy; however, recent studies and current guidelines support its use even in chemotherapy naïve patients .…”